This Phase III, randomized, double-blinded, placebo-controlled, parallel-group study will determine the safety, tolerance and efficacy of two doses of Zaleplon on adult's with primary insomnia or insomnia associated with mild nonpsychotic psychiatric disorders.
Showing the most recent 10 out of 470 publications